Dark Forest Capital Management LP Makes New Investment in Elanco Animal Health Incorporated (NYSE:ELAN)

Dark Forest Capital Management LP bought a new stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 53,994 shares of the company's stock, valued at approximately $654,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Wilmington Savings Fund Society FSB acquired a new stake in Elanco Animal Health in the third quarter valued at $35,000. Jones Financial Companies Lllp lifted its holdings in shares of Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after purchasing an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. grew its position in shares of Elanco Animal Health by 221.2% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after purchasing an additional 3,411 shares during the last quarter. MRP Capital Investments LLC purchased a new position in shares of Elanco Animal Health during the 4th quarter worth approximately $61,000. Finally, Blue Trust Inc. raised its position in shares of Elanco Animal Health by 47.7% during the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after purchasing an additional 1,894 shares during the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Stifel Nicolaus dropped their price target on Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating for the company in a research report on Monday, April 14th. UBS Group reduced their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Barclays decreased their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Piper Sandler reduced their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Finally, Morgan Stanley lowered their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $14.67.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of the stock in a transaction dated Tuesday, March 11th. The stock was bought at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the purchase, the director now directly owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. The trade was a 9.86 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.89% of the stock is owned by corporate insiders.

Elanco Animal Health Trading Up 2.6 %

ELAN stock traded up $0.25 during midday trading on Tuesday, reaching $9.76. 6,441,241 shares of the company's stock traded hands, compared to its average volume of 4,940,238. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $18.80. The business has a 50-day moving average price of $10.00 and a two-hundred day moving average price of $11.58. The company has a market capitalization of $4.84 billion, a P/E ratio of 24.39, a PEG ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the firm posted $0.08 EPS. The business's revenue was down 1.4% compared to the same quarter last year. Equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.